by Avery Zimmerman | Nov 15, 2022 | Blog
In the PDUFA VII Commitment Letter, FDA announced its intention to roll out the Rare Disease Endpoint Advancement (RDEA) Pilot Program next year. This program is intended to address some of the unique challenges rare disease researchers face when determining endpoints...
by Prakash Achaary | Aug 27, 2020 | Blog
[Fill out the form below to access the whitepaper] The Orphan Drug Act, established in 1983, provides incentives to sponsors for promoting the development of drugs for the prevention, diagnoses, and treatment of rare diseases or conditions that affect fewer than...
